Company profile for Aldeyra Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammati...
Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Aldeyra Therapeutics TM, 131 Hartwell Avenue, Suite 320 Lexington, MA 02421
Telephone
Telephone
(781) 761-4904
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251113748228/en/Aldeyra-Therapeutics-Announces-Expansion-of-RASP-Platform-to-Include-Central-Nervous-System-Diseases-and-Provides-Updates-on-Reproxalap-at-Research-Development-Webcast

BUSINESSWIRE
13 Nov 2025

https://www.businesswire.com/news/home/20251111355562/en/Aldeyra-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference-in-London

BUSINESSWIRE
11 Nov 2025

https://www.businesswire.com/news/home/20251106091181/en/Aldeyra-Therapeutics-to-Host-Research-Development-Update-Webcast-Event-Scheduled-for-Thursday-November-13-at-800-a.m.-ET

BUSINESS WIRE
06 Nov 2025

https://www.biospace.com/drug-development/aldeyra-cans-rasp-asset-brings-forward-two-others-in-pipeline-shakeup

BIOSPACE
29 Oct 2025

https://www.businesswire.com/news/home/20251028764760/en/Aldeyra-Therapeutics-Announces-Positive-Results-from-Phase-2-Clinical-Trial-in-Alcohol-Associated-Hepatitis-Focuses-RASP-Product-Candidate-Pipeline-on-Next-Generation-Molecules

BUSINESSWIRE
28 Oct 2025

https://www.pharmiweb.com/press-release/2025-09-03/aldeyra-therapeutics-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference

PHARMAWEB
03 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty